Sökresultat - Marc R. Radke

  • Visas 1 - 13 av 13 resultat
Förfina resultatet
  1. 1
    Rare <i>BRIP1</i> Missense Alleles Confer Risk for Ovarian and Breast Cancer

    Rare <i>BRIP1</i> Missense Alleles Confer Risk for Ovarian and Breast Cancer av Cassandra L. Moyer, Jennifer Ivanovich, Jessica L. Gillespie, Rachel Doberstein, Marc R. Radke, Marcy E. Richardson, Scott H. Kaufmann, Elizabeth M. Swisher, Paul J. Goodfellow

    Publicerad 2019
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  2. 2
    BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance

    BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance av Yifan Wang, Andrea J. Bernhardy, Joseph Nacson, John J. Krais, Yinfei Tan, Émmanuelle Nicolas, Marc R. Radke, Elizabeth Handorf, Alba Llop‐Guevara, Judith Balmañà, Elizabeth M. Swisher, Violeta Serra, Suraj Peri, Neil Johnson

    Publicerad 2019
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  3. 3
    Genomic and epigenomic <i>BRCA</i> alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas

    Genomic and epigenomic <i>BRCA</i> alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas av Francesca Menghi, Kalyan Banda, Pooja Kumar, Robert F. Straub, Lacey E. Dobrolecki, Isabel V. Rodriguez, Susan E. Yost, Harshpreet Chandok, Marc R. Radke, George Somlo, Yuan Yuan, Michael T. Lewis, Elizabeth M. Swisher, Edison T. Liu

    Publicerad 2022
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  4. 4
    Farletuzumab ecteribulin and MORAb‐109, folate receptor alpha and mesothelin targeting antibody–drug conjugates, show activity in poor prognosis gynaecological cancer models

    Farletuzumab ecteribulin and MORAb‐109, folate receptor alpha and mesothelin targeting antibody–drug conjugates, show activity in poor prognosis gynaecological cancer models av Ksenija Nesic, Katherine A. Rybinski, Gayanie Ratnayake, Gwo‐Yaw Ho, Ratana Lim, Marc R. Radke, Chloe Neagle, Elizabeth M. Swisher, Matthew J. Wakefield, Holly E. Barker, Keiji Furuuchi, Clare L. Scott, Cassandra J. Vandenberg

    Publicerad 2025
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  5. 5
    Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

    Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513 av E. Gabriela Chiorean, Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian, Jordan Berlin, Marcus Smith Noel, Jennifer M. Suga, Ignacio Garrido‐Laguna, Dana B. Cardin, Marc R. Radke, Mai Duong, Shay Bellasea, Andrew M. Lowy, Howard S. Höchster

    Publicerad 2021
    Hämta fulltext Hämta fulltext
    Carta
    Lägg till i favoriter
    Sparad:
  6. 6
    <i>BLM</i> overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant <i>BRCA</i> -mutant ovarian cancer

    <i>BLM</i> overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant <i>BRCA</i> -mutant ovarian cancer av Nitasha Gupta, Tzu‐Ting Huang, Jayakumar R. Nair, Daniel An, Grant Zurcher, Erika J. Lampert, Ann McCoy, Ashley Cimino‐Mathews, Elizabeth M. Swisher, Marc R. Radke, Christina M. Lockwood, Jonathan Reichel, Chih-Yuan Chiang, Kelli M. Wilson, Ken Cheng, Darryl Nousome, Jung‐Min Lee

    Publicerad 2023
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  7. 7
    The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial

    The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial av Elena Giudice, Tzu‐Ting Huang, Jayakumar R. Nair, Grant Zurcher, Ann McCoy, Darryl Nousome, Marc R. Radke, Elizabeth M. Swisher, Stanley Lipkowitz, Kristen R. Ibanez, Duncan Donohue, Tyler Malys, Min-Jung Lee, Bernadette Redd, Elliot Levy, Shraddha Rastogi, N Sato, Jane B. Trepel, Jung‐Min Lee

    Publicerad 2024
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  8. 8
    Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

    Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study av Erika J. Lampert, Alexandra S. Zimmer, Michelle R. Padget, Ashley Cimino‐Mathews, Jayakumar R. Nair, Yingmiao Liu, Elizabeth M. Swisher, James W. Hodge, Andrew B. Nixon, E. Hitt Nichols, Mohammadhadi Bagheri, Elliott Levy, Marc R. Radke, Stanley Lipkowitz, Christina M. Annunziata, Janis M. Taube, Seth M. Steinberg, Jung‐Min Lee

    Publicerad 2020
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  9. 9
    Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial

    Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled,... av Eve T. Rodler, Priyanka Sharma, William E. Barlow, Julie R. Gralow, Shannon L. Puhalla, Carey K. Anders, Lori J. Goldstein, Debu Tripathy, Ursa Brown‐Glaberman, Thu-Tam Huynh, Christopher S Szyarto, Andrew K. Godwin, Harsh B. Pathak, Elizabeth M. Swisher, Marc R. Radke, Kirsten M. Timms, Danika L. Lew, Jieling Miao, Lajos Pusztai, Daniel F. Hayes, Gabriel N. Hortobágyi

    Publicerad 2023
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  10. 10
    Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984

    Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984 av Joseph W. Kim, Rana R. McKay, Marc R. Radke, Shilin Zhao, Mary‐Ellen Taplin, Nancy B. Davis, Paul Monk, Leonard J. Appleman, Primo N. Lara, Ulka N. Vaishampayan, Jingsong Zhang, Asit K. Paul, Glenn J. Bubley, Eliezer M. Van Allen, Serhan Ünlü, Ying Huang, Massimo Loda, Geoffrey I. Shapiro, Peter M. Glazer, Patricia LoRusso, S. Percy Ivy, Yu Shyr, Elizabeth M. Swisher, Daniel P. Petrylak

    Publicerad 2022
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  11. 11
    <i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

    <i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma av Kevin Lin, Maria I. Harrell, Amit M. Oza, Ana Oaknin, Isabelle Ray‐Coquard, Anna V. Tinker, Elena Helman, Marc R. Radke, Carmen Say, Lan-Thanh Vo, Elaina Mann, Jeffrey D. Isaacson, Lara Maloney, David M. O’Malley, Setsuko K. Chambers, Scott H. Kaufmann, Clare L. Scott, Gottfried E. Konecny, Robert L. Coleman, James Sun, Heidi Giordano, James D. Brenton, Thomas C. Harding, Iain A. McNeish, Elizabeth M. Swisher

    Publicerad 2018
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  12. 12
    Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma

    Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma av Ksenija Nesic, Olga Kondrashova, Rachel M. Hurley, Cordelia D. McGehee, Cassandra J. Vandenberg, Gwo‐Yaw Ho, Elizabeth Lieschke, Genevieve Dall, Nirashaa Bound, Kristy Shield‐Artin, Marc R. Radke, Ashan Musafer, Zi Qing Chai, Mohammad Reza Eftekhariyan Ghamsari, Maria I. Harrell, Damien Kee, Inger Olesen, Orla McNally, Nadia Traficante, Australian Ovarian Cancer Study, Anna deFazio, David D.L. Bowtell, Elizabeth M. Swisher, S. John Weroha, Kátia Nones, Nicola Waddell, Scott H. Kaufmann, Alexander Dobrovic, Matthew J. Wakefield, Clare L. Scott

    Publicerad 2021
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  13. 13
    BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance

    BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance av Ksenija Nešić, John J. Krais, Yifan Wang, Cassandra J. Vandenberg, Pooja Patel, Kathy Q. Cai, Tanya T. Kwan, Elizabeth Lieschke, Gwo‐Yaw Ho, Holly E. Barker, Justin Bedő, Silvia Casadei, Andrew Farrell, Marc R. Radke, Kristy Shield‐Artin, Jocelyn Sietsma Penington, Franziska Geissler, Elizabeth L. Kyran, Robert Betsch, Lijun Xu, Fan Zhang, Alexander Dobrovic, Inger Olesen, Rebecca Kristeleit, Amit M. Oza, Iain A. McNeish, Gayanie Ratnayake, Nadia Traficante, Georgia Chenevix‐Trench, A Green, Penelope M. Webb, Dorota M. Gertig, Sián Fereday, Suzanne Moore, Jillian A. Hung, K.R. Harrap, T. Sadkowsky, Nirmala Pandeya, M. Malt, A. Mellon, R. Paul Robertson, T. Vanden Bergh, Milissa U. Jones, P. Mackenzie, J. Maidens, K. Nattress, Yoke-Eng Chiew, Annie Stenlake, Harold C. Sullivan, Brian M. Alexander, P. Ashover, Stephen M. Brown, T. Corrish, L. Green, L. M. Jackman, Kaltin Ferguson, Karla Martin, A. Martyn, B. Ranieri, J. White, V. Jayde, Pam Mamers, Leanne Bowes, Laura Galletta, Daniel A. Giles, Joy Hendley, Thomas Schmidt, H. Shirley, C. Ball, Christian D. Young, S. Viduka, Hang Tran, Sanela Bilic, Lydia Glavinas, Julia Brooks, R. Stuart‐Harris, Fred Kirsten, J Rutovitz, P. Clingan, Akisha Glasgow, Anthony Proietto, Stephen Braye, Geoffrey Otton, Jenny Shannon, Tony Bonaventura, James Stewart, Stephen Begbie, Michael Friedlander, Debra Bell, Sally Baron‐Hay, A. Ferrier, G. Gard, David Nevell, Nick Pavlakis, Susan Valmadre, Bruce W. Young, C. Camaris, R. Crouch, L. Edwards, Neville F. Hacker

    Publicerad 2024
    Hämta fulltext
    Carta
    Lägg till i favoriter
    Sparad:

Sökverktyg: